Update from Operation Warp Speed on Monoclonal Antibodies and Convalescent Plasma

This week’s update from Operation Warp Speed included updates on the distribution of Regeneron’s monoclonal antibody cocktail and a call for Americans to donate Convalescent Plasma.

THERAPEUTICS DEVELOPMENT:

Regeneron announced its monoclonal antibody cocktail – casirivimab and imdevimab administered together – received Emergency Use Authorization by the FDA. Operation Warp Speed began distribution of the new drug cocktail this week where it is needed most around the country. The treatment is authorized for mild to moderate COVID-19 in adults and pediatric patients at least 12 years old who weigh at least 40 kg or 88 pounds and are at high risk for progressing to severe COVID-19 or hospitalization.

Operation Warp Speed’s Deputy Lead for Therapeutics Col. Deydre Teyhen discusses the types of treatments, ongoing research and the continued importance of ongoing research to treat COVID-19 in a video interview

As COVID-19 infections spike nationwide, the demand for convalescent plasma is outpacing donations. Americans who have recovered from COVID-19 in the last three months can donate now. Go to your local blood collection center, American Red Cross or America’s Blood Centers or visit www.TheFightIsInUs.org to become a donor.

This Week in Operation Warp Speed – Nov. 27, 2020

Further Reading:

Update from Operation Warp Speed on Monoclonal Antibodies and Convalescent Plasma
Scroll to top